[Factor VII, a therapeutic alternative in the treatment of severe haemoghage disorders].
Plasmatic coagulation has like purpose the formation of a stable clot of fibrina, this process is possible thanks to the intervention of the factors of the coagulation that are plasmatic proteins. Some of these factors are vitamin K dependent (factors II, VII, IX and X) and all except for the factors VIII, XII and XIII which are synthesized in the liver. Three clinical cases of patients are described who present serious hemorrhagic disorders, associated to different hepatic alterations, which do not respond to conventional treatments. As a measure of urgency and therapeutic alternative, the administration of recombinant factor VII is used with the aim of activating the extrinsic pathway of the coagulation and of obtaining a positive answer in the control of the hemorrhage.
Morales León
V
V
Servicio de Farmacia, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, 35020 Spain. victormorales@redfarma.es
Herrera Ortega
G
G
Molero Gómez
R
R
García Cortés
J
J
D000328:Adult; D001943:Breast Neoplasms / Q000150:complications; D005167:Factor VII / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008099:Liver / Q000293:injuries; D008107:Liver Diseases / Q000150:complications; D008108:Liver Diseases, Alcoholic / Q000150:complications; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005167:Factor VII